Biosimilars
The Global Division of Labor Behind the Coming Oncology Biosimilar Wave
Pharma's Almanac
PAO-09-26-PA-18Sep 15, 2026
Partnership
Samsung Biologics Signs USD 262 Million Manufacturing Agreement with European Pharmaceutical Company
Samsung Biologics
PR-09-26-02Sep 10, 2026
CDMO Governance
The Governance Gap: Why Good CDMO Partnerships Still Fail
Pharma's Almanac
PAO-09-26-PA-07Sep 9, 2026
CDMO Consolidation
How Far Should CDMO Network Consolidation Go?
Pharma's Almanac
PAO-09-26-PA-06Sep 8, 2026
Partner Selection
How are organizations balancing cost with regulatory, supply chain, and reputational risk when selecting partners or sites?
Pharma's Almanac
PAO-08-26-RT-01Aug 28, 2026
Innovation Partner
CDMOs as Innovation Partners in R&D
Prateek Gupta, Ph.D.
OneSource Specialty Pharma
PAO-08-26-CL-05Aug 6, 2026
Cell Therapy
NueCell Bio Launches as a New Translational Partner to Accelerate Cell Therapies from Discovery into GMP Manufacturing
NueCell Bio
PR-08-26-01Aug 5, 2026
CRO Partnerships
Building Resilient Development Models: How Mid-Size Pharma Can Scale Without Losing Control
Brian Healey
IQVIA
PAO-06-26-CL-02Jun 17, 2026
Research Collab
10x Genomics and Cleveland Clinic Collaborate in Diagnostic Applications of Single Cell and Spatial Technologies in Bladder Cancer
10x Genomics
PR-06-26-02Jun 17, 2026
Partnership
The Solubility Company and Persist AI Unveil Strategic Partnership to Bridge the Data Gap in AI-Driven Drug Formulation
The Solubility Company
PR-05-26-02May 13, 2026
Outsourcing Regs
Navigating Global Regulatory Expectations in Outsourced Manufacturing
David Alvaro, Ph.D.
Pharma's Almanac
PAO-04-26-PA-07Apr 10, 2026
Formulation
Quotient Sciences and Intrepid Labs form Strategic Partnership to Accelerate AI-guided Formulation Development
Quotient Sciences
PR-04-26-05Apr 1, 2026
Clinical Partnership
Quotient Sciences and Biorasi Partner to Accelerate Early Phase Clinical Trials to Patient Proof-of-Concept
Quotient Sciences
PR-04-26-04Apr 1, 2026
Drug Development
Lindus Health and Quotient Sciences Partner to Accelerate Drug Development from First-in-Human to Pivotal Trials
Quotient Sciences
PR-04-26-03Apr 1, 2026
Rare Disease
Quotient Sciences Extends Commercial Manufacturing Partnership for Ultra-Rare Disease Treatment
Quotient Sciences
PR-04-26-02Apr 1, 2026
EU Public–Private
Europe’s Innovation Engine: How Public–Private Partnerships Are Transforming Biomedical Research
David Alvaro, Ph.D.
Pharma's Almanac
PAO-03-26-PA-11Mar 18, 2026
Partnerships
What does a “true strategic partnership” between sponsors and CDMOs look like in today’s environment?
Pharma's Almanac
PAO-03-26-RT-01Mar 1, 2026
Risk Sharing
Risk-Sharing Rewritten: How Biopharma Partnerships Are Redesigning Incentives Beyond the Deal
David Alvaro, Ph.D.
Pharma's Almanac
PAO-01-26-NI-05Jan 9, 2026
CDMO Excellence
Delivering CDMO Excellence, Quality, and Value through Dedication
Adriana Kiędzierska–Mencfeld, Ph.D.
Rezon Bio
PAO-12-25-CL-01Dec 2, 2025
Collaboration
TegMine Therapeutics Enters Collaboration with Boehringer Ingelheim to Advance Novel 2-Factor Antibody System for Cancer
Tegmine Therapeutics
PR-09-25-NI-05Sep 23, 2025